Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Moving Aggressively – Down $0.04


Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) last traded at $1.14 with shares having a low of $1.13 and high of $1.23. The swing tags the stock as one of the most volatile of the day.

Company shares last traded at $1.14 just a bit lower than the 50 day moving average which is $1.15 and which is quite a bit below the 200 day moving average of $1.83. The 50 day moving average was down by -0.2581% and the 200 day average was down $-0.69.

Short Interest

Traders are a little more bullish on the company recently if you put credence in the downtick in short interest. The firm experienced a fall in short interest between August 15, 2017 and August 31, 2017 of -22.48%. Short shares decreased from 1,172,061 to 908,639 over that timeframe. Days to cover decreased from 3.0 to 1.0 and the percentage of shorted shares is 0.02% as of August 31. In the last earnings report the EPS was $-1.39 and is estimated to be $-0.92 for the current year with 50,689,000 shares presently outstanding. Next quarter’s EPS is forecasted to be $-0.20 and the next full year EPS is projected to be $-1.50.

Company Information

Infinity Pharmaceuticals, Inc., launched on May 11, 2000, is a biopharmaceutical company. The Company is involved in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology..